Pureos Bioventures leads CHF 10m series-A for NovaGo

Swiss clinical-stage biotech company Neurimmune also took part in the investment.

Pureos partner Dominik Escher will join NovaGo's board of directors.

The company plans to use the fresh capital to develop its regenerative therapeutics towards clinical trials.

Company
Founded in 2015 as a spin-out from the University of Zurich, NovaGo specialises in developing human antibody therapeutics to help patients recover from cerebral stroke and spinal cord injuries by stimulating nerve repair and regeneration.

People
Pureos Bioventures – Dominik Escher (partner).
NovaGo Therapeutics – Martin Schwab (founder, president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland